Table 1. Proven and putative human interacting partners of AIP (human proteins only)*.
| UniProt entry | Protein name (gene) | Experimental method | References |
|---|---|---|---|
| P60709 | Actin, cytoplasmic 1 (ACTB)¶ | AC-MS | [64] |
| Q9UL18 | Argonaute RISC catalytic component 1 (AGO1) | AC-MS, co-IP | [95] |
| P35869 | Aryl hydrocarbon receptor (AHR) | Co-IP | [8, 64, 96] |
| RC | [8, 9, 16, 97] | ||
| 2H | [8, 16, 98] | ||
| P27540 | Aryl hydrocarbon receptor nuclear translocator (ARNT)† | Co-IP | [64] |
| RC | [16, 57] | ||
| 2H | [9] | ||
| O15392 | Baculoviral IAP repeat-containing protein 5 (BIRC5) | AC-MS, co-IP | [21] |
| Q9BXL7 | Caspase recruitment domain-containing protein 11 (CARD11) | 2H, co-IP | [99] |
| Q96HB5 | Coiled-coil domain containing protein 120 (CCDC120) | AC-MS | [100] |
| Q16543 | Hsp90 co-chaperone cell division cycle 37 (CDC37) | AC-L, AC-MS | [101] |
| P50750 | Cyclin-dependent kinase 9 (CDK9) | AC-MS | [61, 100] |
| Q9BXN2 | C-type lectin domain family 7, member A (CLEC7A) | 2H | [102] |
| P68400 | Casein kinase 2, alpha 1 polypeptide (CSNK2A1) | BA | [103] |
| Q9NVR5 | Protein kintoun (DNAAF2) | AC-L, AC-MS | [101] |
| P00533 | Epidermal growth factor receptor (EGFR) | PCA | [104] |
| P41091 | Eukaryotic translation initiation factor 2 subunit 3 (EIF2S3) | Co-F | [105] |
| P03372 | Oestrogen receptor (ESR1) | Co-IP | [106] |
| Q9UK99 | F-box only protein 3 (FBXO3) | Co-IP, AC-MS | [7] |
| P50395 | Rab GDP dissociation inhibitor beta (GDIB) | Co-F | [107] |
| Q14344 | Guanine nucleotide-binding protein subunit alpha 13 (GNA13) | RC, 2H | [108] |
| P50148 | Guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) | RC | [108] |
| P11142 | Heat shock cognate 71 kDa protein (HSPA8) | Co-IP | [20] |
| P07900 | Heat shock protein 90-alpha (HSP90AA1) | AC-L, AC-MS | [101] |
| RC | [52, 57, 97] | ||
| P08238 | Heat shock protein 90-beta (HSP90AB1) | AC-L, AC-MS | [101] |
| Co-IP | [9, 18, 20, 55, 57, 97, 109–111]§ | ||
| P38646 | Stress-70 protein, mitochondrial (HSPA9) | Co-F | [105] |
| Q9Y6K9 | NF-kappa-B essential modulator (IKBKG) | 2H | [112] |
| Q92985 | Interferon regulatory factor 7 (IRF7) | AC-MS, RC | [113] |
| Co-IP | [114] | ||
| P11279 | Lysosome-associated membrane glycoprotein 1 (LAMP1) | Co-F | [105] |
| Q9NZR2 | Low-density lipoprotein receptor-related protein 1B (LRP1B) | 2H, co-IP | [115] |
| Q9NXB0 | Meckel syndrome type 1 protein (MKS1) | PL-MS | [116] |
| Q6IA69 | Glutamine-dependent NAD(+) synthetase (NADSYN1) | AC-L, AC-MS | [101] |
| Q86SG6 | Serine/threonine-protein kinase Nek8 (NEK8) | PL-MS | [116] |
| Q8WWR8 | Sialidase-4 (NEU4) | AC-MS | [100] |
| O75161 | Nephrocystin-4 (NPHP4) | PL-MS | [116] |
| P08235 | Mineralocorticoid receptor (NR3C2) | Co-IP | [111] |
| O75665 | Oral-facial-digital syndrome 1 protein (OFD1) | PL-MS | [116] |
| P27815 | cAMP-specific 3’,5’-cyclic phosphodiesterase 4A (PDE4A) | 2H | [30, 90, 117] |
| Co-IP | [117] | ||
| O00408 | cGMP-dependent 3’,5’-cyclic phosphodiesterase 2A (PDE2A) | 2H, co-IP, co-loc | [118] |
| Q15181 | Inorganic pyrophosphatase (PPA1) | Co-F | [119] |
| Q9H2U2 | Inorganic pyrophosphatase 2, mitochondrial (PPA2) | Co-F | [119] |
| Q07869 | Peroxisome proliferator-activated receptor alpha (PPARA) | Co-IP, RC | [120] |
| O75170 | Serine/threonine-protein phosphatase 6 regulatory subunit 2 (PPP6R2) | PL-MS | [121] |
| O60809 | PRAME family member 10 (PRAMEF10) | AC-MS | [100] |
| Q5VTA0 | PRAME family member 10 (PRAMEF17) | AC-MS | [100] |
| P48147 | Prolyl endopeptidase (PREP) | Co-F | [119] |
| Q15185 | Prostaglandin E synthase 3 (PTGES3) | AC-L, AC-MS | [101] |
| Co-IP | [111] | ||
| P07949 | Rearranged during transfection tyrosine-kinase receptor (RET) | Co-IP, PCA | [122] |
| P31948 | Stress-induced phosphoprotein 1 (STIP1) | RC | [52] |
| Q9Y2Z0 | Suppressor of G2 allele of SKP1 homolog (SUGT1) | AC-L, AC-MS | [101] |
| P13385 | Teratocarcinoma-derived growth factor 1 (TDGF1) | AC-MS | [100] |
| Q59H18 | TNNI3 interacting kinase (TNNI3K) | 2H | [123] |
| Q15388 | Mitochondrial import receptor subunit TOM20 homolog (TOMM20) | 2H, co-IP | [20] |
| RC | [11] | ||
| P10828 | Thyroid hormone receptor beta (THRB) | 2H | [124] |
| P0CG48 | Polyubiquitin C (UBC) | AC-MS | [125–129] |
| Q6PHR2 | Serine/threonine-protein kinase ULK3 (ULK3) | AC-MS | [100] |
| O94966 | Ubiquitin specific peptidase 19 (USP19) | AC-L, AC-MS | [101] |
| P07947 | Tyrosine-protein kinase Yes (YES1) | AC-MS | [100] |
Abbreviations: 2H: two-hybrid assay, AC-L: Affinity capture-luminescence, AC-MS: affinity capture (pull-down)-mass spectrometry, BA: biochemical activity (an interaction is inferred from the biochemical effect of one protein upon another), co-F: co-fractionation, co-IP: co-immunoprecipitation (affinity capture-Western blot), co-loc: co-localization, PCA: protein-fragment complementation assay, PL-MS: proximity label-mass spectrometry, RC: reconstituted complex (an interaction is detected between two proteins in vitro). Detailed explanation of all the experimental methods: http://wiki.thebiogrid.org/doku.php/experimental_systems.
*Includes proteins detected either by direct protein-protein interaction experiments or as part of datasets from high-throughput proteomic studies reported in the literature and/or in the Biological General Repository for Interaction Datasets [26].
¶Contradictive results, a direct interaction between AIP and ACTB was disproven by a different study [65].
†Contradictive results, a direct interaction between AIP and ARNT was disproven by different studies [8, 16, 109].
§These studies did not specify the isoform of HSP90 analyzed or used a peptide that is common to HSP90AA1 and HSP90AB1.